Prostatic Neoplasms, Castration-Resistant Clinical Trials
46 clinical trials for Prostatic Neoplasms, Castration-Resistant across international registries, including 14 currently recruiting participants. Compare status, phase, eligibility criteria and locations.
- A Study in Patients With Metastatic Castration-Resistant Prostate Cancer — RECRUITING · PHASE1
- A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring — RECRUITING · PHASE1
- A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer — RECRUITING · PHASE3
- Fractionated Stereotactic Radiotherapy Plus Second-generation Antiandrogen for Oligometastatic Castration-resistant Prostate Cancer Patients. — RECRUITING · PHASE2
- A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas — RECRUITING · PHASE1
- A Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer — RECRUITING
- A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan — RECRUITING
- Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) — RECRUITING · PHASE1
- 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE) — RECRUITING · PHASE1
- Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer — RECRUITING · PHASE1
- Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer — RECRUITING · PHASE1
- HTL0039732 in Participants With Advanced Solid Tumours — RECRUITING · PHASE1
- 18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer — RECRUITING · PHASE4
- Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC — RECRUITING · PHASE2
- Pluvicto Real-world Investigation in Survival in Metastatic CRPC — NOT_YET_RECRUITING
- A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer — ACTIVE_NOT_RECRUITING · PHASE2
- A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer — ACTIVE_NOT_RECRUITING · PHASE1
- Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer — ACTIVE_NOT_RECRUITING · PHASE1
- A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer — COMPLETED
- Development and Prospective Validation of a Pathology-Based Artificial Intelligence Model for Predicting the Time to Castration Resistance of Prostate Cancer — NOT_YET_RECRUITING
- Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer — COMPLETED · PHASE2
- Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer — COMPLETED · PHASE1
- BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC) — COMPLETED · PHASE1
- Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases — COMPLETED
- A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer — TERMINATED · PHASE2
- Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of Prostate Cancer — COMPLETED · PHASE2
- P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) — TERMINATED · PHASE1
- Survival Outcomes in Metastatic Prostate Cancer in the Brazilian Population - Analysis of Individual Characteristics and Treatment Modalities in Different National Health Institutions. — ACTIVE_NOT_RECRUITING
- Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants With Metastatic Castration-resistant Prostate Cancer — COMPLETED · PHASE1
- Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) — COMPLETED
- A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen — COMPLETED · PHASE3
- A COMbined progRamme of Exercise and Dietary ADvice in mEn With Castrate Resistant Prostate Cancer — COMPLETED · NA
- 68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer — COMPLETED · PHASE2
- Effect of a Reduced Dose Enzalutamide in Frail (m)CRPC Patients on Cognitive Side Effects — COMPLETED · PHASE4
- 68Ga PSMA in Preprostatectomy Patients — COMPLETED · PHASE2
- Actium-225-Prostate Specific Membrane Antigen Imaging & Therapy — OTHER · PHASE1
- 68Ga-PSMA-11 Patients With Newly Diagnosed and Recurrent Prostate Cancer (Firefly) — TERMINATED
- TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer — OTHER · PHASE2
- Non-interventional Study With Ra-223 Dichloride Assessing Overall Survival and Effectiveness Predictors for mCRPC Patients in a Real Life Setting in Germany — COMPLETED
- Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer — TERMINATED · PHASE3
- Efficacy of Rotations Between Abiraterone Acetate and Apalutamide in mCRPC Patients — WITHDRAWN · PHASE2
- A Local Retrospective Observational Study to Evaluate the Treatment Patterns of mCRPC Patients in Belgium Treated With Radium-223 — COMPLETED
- A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer — COMPLETED · PHASE1
- Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer ) — COMPLETED
- Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study — WITHDRAWN
- A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer — WITHDRAWN · PHASE2
Refine this search